Has Mark Shepherd, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,328 in general payments to Mark Shepherd, MD across 1,090 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Shepherd, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Shepherd, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Shepherd, MD

Endocrinology, Diabetes & Metabolism · Tupelo, MSNPI 1760499867

Payments from drug & device makers

$17,328in general payments, 2019–2025

Across 1,090 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$2K
Novo Nordisk$1K
Amgen$1K
Abbott$1K
Insulet Corporation$1K
Xeris Pharmaceuticals, Inc.$1K
plus $9K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	149	$2,011
Novo Nordisk	116	$1,445
Amgen(2 entities)	87	$1,277
Abbott	56	$1,133
Insulet Corporation	47	$1,115
Xeris Pharmaceuticals, Inc.	56	$1,092
Corcept Therapeutics	48	$919
Medtronic(2 entities)	50	$903
Dexcom, Inc.	44	$740
AbbVie	50	$671
Boehringer Ingelheim	50	$641
Sanofi-aventis U.S. LLC	47	$613
AstraZeneca(2 entities)	28	$444
Radius Health, Inc.	24	$430
Amarin Pharma, Inc.	32	$409
Bayer	24	$385
Mannkind Corporation	22	$362
Johnson & Johnson	16	$231
Merck	15	$218
Recordati_rare_diseases_inc.	12	$214
Eisai Inc.	8	$161
Pfizer	10	$161
Sequel Med Tech, LLC	6	$145
Shire North American Group Inc	12	$136
Esperion Therapeutics, Inc.	8	$122
Tandem Diabetes Care, Inc.	6	$106
Amryt Pharma Holdings Ltd	5	$93
RGH Enterprises LLC	2	$78
Endo Pharmaceuticals Inc.	5	$78
Antares Pharma, Inc.	3	$72
Alnylam Pharmaceuticals Inc.	4	$72
Sanofi	3	$68
Regeneron Healthcare Solutions, Inc.	3	$67
Ascendis Pharma Endocrinology Inc	4	$63
Neurocrine Biosciences, Inc.	2	$57
Ultragenyx Pharmaceutical Inc.	3	$55
Madrigal Pharmaceuticals	2	$44
Vivus LLC	4	$42
Endo USA, Inc.	2	$41
BD	2	$40
Soleno Therapeutics, Inc.	2	$38
Travere Therapeutics, Inc.	3	$36
Kyowa Kirin, Inc.	2	$33
Cequr Corporation	1	$29
Kowa Pharmaceuticals America, Inc.	2	$28
Halozyme Inc	1	$23
Embecta Corp.	1	$22
Novartis	1	$22
Chiesi USA, Inc.	1	$20
Ascensia Diabetes Care US Inc.	1	$17
Rochester Medical Corporation	1	$17
Acella Pharmaceuticals, LLC	1	$17
EUSA Pharma (US) LLC	1	$16
GSK	1	$14
Ionis Pharmaceuticals, Inc.	1	$14
Lifescan, Inc.	1	$11
Takeda Pharmaceuticals U.S.A., Inc.	1	$11
Azurity Pharmaceuticals, Inc.	1	$7

How this compares

$17,328 in reported general payments places this provider in the 70th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi →

Medicare billing

Part B allowed, 2024

$582,205

Medicare patients

1,641

Services billed

28,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Tupelo

Christy OswaltTupelo$27K
Leonil GanlimTupelo$19K
Jayant DeyTupelo$1K
Mark BorcheltGulfport$1.1M
Honey EastJackson$904K
Eric DyessJackson$885K
Ben SealeJackson$623K
Jeremy TaylorMadison$271K
Amanda SchieferJackson$204K
Delali BlavoSouthaven$148K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →